메뉴 건너뛰기




Volumn 14, Issue 1, 2015, Pages 101-110

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CRIZOTINIB; HGF MET FACTOR; PROTEIN; SCATTER FACTOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; SCATTER FACTOR RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

EID: 84961287855     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0094     Document Type: Article
Times cited : (88)

References (29)
  • 4
    • 0036242160 scopus 로고    scopus 로고
    • Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas
    • Oh RR, Park JY, Lee JH, Shin MS, Kim HS, Lee SK, et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. Acta Pathol Microbiol Immunol Scand 2002;110: 229-38.
    • (2002) Acta Pathol Microbiol Immunol Scand , vol.110 , pp. 229-238
    • Oh, R.R.1    Park, J.Y.2    Lee, J.H.3    Shin, M.S.4    Kim, H.S.5    Lee, S.K.6
  • 6
    • 14644440555 scopus 로고    scopus 로고
    • Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    • Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23: 1011-27.
    • (2005) J Clin Oncol , vol.23 , pp. 1011-1027
    • Hicklin, D.J.1    Ellis, L.M.2
  • 7
    • 47949089077 scopus 로고    scopus 로고
    • VEGF-targeted therapy: Mechanisms of anti-tumour activity
    • Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev Cancer 2008;8: 579-91.
    • (2008) Nature Rev Cancer , vol.8 , pp. 579-591
    • Ellis, L.M.1    Hicklin, D.J.2
  • 8
    • 34548316976 scopus 로고    scopus 로고
    • Molecular basis for sunitinib ef ficacy and future clinical development
    • Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib ef ficacy and future clinical development. Nature Rev Drug Discov 2007;6: 734-45.
    • (2007) Nature Rev Drug Discov , vol.6 , pp. 734-745
    • Faivre, S.1    Demetri, G.2    Sargent, W.3    Raymond, E.4
  • 9
    • 82755183572 scopus 로고    scopus 로고
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
    • Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378: 1931-9.
    • (2011) Lancet , vol.378 , pp. 1931-1939
    • Rini, B.I.1    Escudier, B.2    Tomczak, P.3    Kaprin, A.4    Szczylik, C.5    Hutson, T.E.6
  • 10
    • 84876974877 scopus 로고    scopus 로고
    • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial
    • Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14: 552-62.
    • (2013) Lancet Oncol , vol.14 , pp. 552-562
    • Motzer, R.J.1    Escudier, B.2    Tomczak, P.3    Hutson, T.E.4    Michaelson, M.D.5    Negrier, S.6
  • 11
    • 58149337448 scopus 로고    scopus 로고
    • Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
    • Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14: 7272-83.
    • (2008) Clin Cancer Res , vol.14 , pp. 7272-7283
    • Hu-Lowe, D.D.1    Zou, H.Y.2    Grazzini, M.L.3    Hallin, M.E.4    Wickman, G.R.5    Amundson, K.6
  • 12
    • 47949099628 scopus 로고    scopus 로고
    • Modes of resistance to anti-angiogenic therapy
    • Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Rev Cancer 2008;8: 592-603.
    • (2008) Nature Rev Cancer , vol.8 , pp. 592-603
    • Bergers, G.1    Hanahan, D.2
  • 13
    • 84866693927 scopus 로고    scopus 로고
    • Controlling escape from angiogenesis inhibitors
    • Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012;12: 699-709.
    • (2012) Nat Rev Cancer , vol.12 , pp. 699-709
    • Sennino, B.1    McDonald, D.M.2
  • 14
    • 78649420006 scopus 로고    scopus 로고
    • MET signalling: Principles and functions in development, organ regeneration and cancer
    • Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11: 834-48.
    • (2010) Nat Rev Mol Cell Biol , vol.11 , pp. 834-848
    • Trusolino, L.1    Bertotti, A.2    Comoglio, P.M.3
  • 15
    • 0036221263 scopus 로고    scopus 로고
    • Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
    • Danilkovitch-miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109: 863-7.
    • (2002) J Clin Invest , vol.109 , pp. 863-867
    • Danilkovitch-Miagkova, A.1    Zbar, B.2
  • 16
    • 84863754907 scopus 로고    scopus 로고
    • VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
    • Lu K V, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22: 21-35.
    • (2012) Cancer Cell , vol.22 , pp. 21-35
    • Lu, K.V.1    Chang, J.P.2    Parachoniak, C.A.3    Pandika, M.M.4    Aghi, M.K.5    Meyronet, D.6
  • 17
    • 84877098516 scopus 로고    scopus 로고
    • Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance
    • Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu Y-L, Lu K, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013;19: 1773-83.
    • (2013) Clin Cancer Res , vol.19 , pp. 1773-1783
    • Jahangiri, A.1    De Lay, M.2    Miller, L.M.3    Carbonell, W.S.4    Hu, Y.-L.5    Lu, K.6
  • 18
    • 78650339354 scopus 로고    scopus 로고
    • HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors
    • Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee Pa, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70: 10090-100.
    • (2010) Cancer Res , vol.70 , pp. 10090-10100
    • Shojaei, F.1    Lee, J.H.2    Simmons, B.H.3    Wong, A.4    Esparza, C.O.5    Plumlee, Pa.6
  • 19
    • 34249324494 scopus 로고    scopus 로고
    • An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
    • Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67: 4408-17.
    • (2007) Cancer Res , vol.67 , pp. 4408-4417
    • Zou, H.Y.1    Li, Q.2    Lee, J.H.3    Arango, M.E.4    McDonnell, S.R.5    Yamazaki, S.6
  • 20
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    • Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. NEJM 2013;368: 2385-94.
    • (2013) NEJM , vol.368 , pp. 2385-2394
    • Shaw, A.T.1    Kim, D.-W.2    Nakagawa, K.3    Seto, T.4    Crinó, L.5    Ahn, M.-J.6
  • 21
    • 77953467629 scopus 로고    scopus 로고
    • Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study
    • Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010;9: 1525-35.
    • (2010) Mol Cancer Ther , vol.9 , pp. 1525-1535
    • Hammers, H.J.1    Verheul, H.M.2    Salumbides, B.3    Sharma, R.4    Rudek, M.5    Jaspers, J.6
  • 22
    • 78650900647 scopus 로고    scopus 로고
    • ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67
    • Tuominen VJ, Ruotoistenmäki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010;12: R56.
    • (2010) Breast Cancer Res , vol.12 , pp. R56
    • Tuominen, V.J.1    Ruotoistenmäki, S.2    Viitanen, A.3    Jumppanen, M.4    Isola, J.5
  • 23
    • 84863704553 scopus 로고    scopus 로고
    • Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors
    • Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2: 270-87.
    • (2012) Cancer Discov , vol.2 , pp. 270-287
    • Sennino, B.1    Ishiguro-Oonuma, T.2    Wei, Y.3    Naylor, R.M.4    Williamson, C.W.5    Bhagwandin, V.6
  • 24
    • 77958072683 scopus 로고    scopus 로고
    • Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
    • Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010;9: 2793-802.
    • (2010) Mol Cancer Ther , vol.9 , pp. 2793-2802
    • Bhatt, R.S.1    Wang, X.2    Zhang, L.3    Collins, M.P.4    Signoretti, S.5    Alsop, D.C.6
  • 26
    • 0026722243 scopus 로고
    • Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
    • Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119: 629-41.
    • (1992) J Cell Biol , vol.119 , pp. 629-641
    • Bussolino, F.1    Di Renzo, M.F.2    Ziche, M.3    Bocchietto, E.4    Olivero, M.5    Naldini, L.6
  • 28
    • 84862657056 scopus 로고    scopus 로고
    • Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme
    • Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 2012;31: 3039-50.
    • (2012) Oncogene , vol.31 , pp. 3039-3050
    • Jun, H.J.1    Acquaviva, J.2    Chi, D.3    Lessard, J.4    Zhu, H.5    Woolfenden, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.